ArticleJournal of medical imaging and radiation oncology2026
Utility of SUVmax on Primary Staging 68Ga-PSMA PET/CT in Determining Metastatic Status of Prostate Cancer.
Article in Journal of medical imaging and radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Utility of SUVmax on Primary Staging 68Ga-PSMA PET/CT in Determining Metastatic Status of Prostate Cancer.Journal of medical imaging and radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction68Ga prostate-specific membrane antigen (PSMA) has been shown to have prognostic value in detecting PSMA expressing metastasis from prostate cancer, but inevitably, there are cases in which suspected metastases demonstrate equivocal uptake. This study aims to assess whether there is a direct relationship between SUVmax of the primary prostate lesion and the presence of nodal and distant metastasis.
methodsRetrospective review of 265 primary staging 68Ga-PSMA PET/CT studies performed at a single centre on a single PET/CT was performed for the SUVmax of the primary lesion, and the presence of PSMA-avid nodal/distant metastases.
resultsAnalysis shows that a single unit increase in SUVmax of the primary prostatic lesion corresponds with a 1.6% increased odds of nodal metastases, 1.7% increased odds of distant metastases and a 2% increased odds of having either. A single unit increase in the log of the SUVmax corresponds with odds ratios of 2.061, 2.038 and 2.294 respectively.
conclusionThere is a weak but statistically significant correlation between the SUVmax of the primary prostate lesion and the presence of metastases on primary staging 68Ga-PSMA PET/CT for biopsy-proven prostate cancer. However, because the relationship is so weak and the significant overlap in SUVmax in local versus advanced disease, using SUVmax as the sole predictor of advanced disease is unreliable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.